Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers exhibit immune regulatory actions by inhibiting proinflammatory cytokine secretion and normalizing CRP concentrations.
Do ACE inhibitors and ARBs have immunomodulatory properties in hypertensive patients and experimental models?
ACE inhibitors and ARBs possess immunomodulatory properties that may benefit patients with comorbidities involving chronic inflammatory responses, such as metabolic syndrome, allergies, or autoimmune disorders.
This review article is focused on antihypertensive drugs, namely angiotensin converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB), and their immunomodulatory properties reported in hypertensive patients as well as in experimental settings involving studies on animal models and cell lines. The immune regulatory action of ACEI and ARB is mainly connected with the inhibition of proinflammatory cytokine secretion, diminished expression of adhesion molecules, and normalization of CRP concentration in the blood plasma. The topic has significant importance in future medical practice in the therapy of patients with comorbidities with underlying chronic inflammatory responses. Thus, this additional effect of immune regulatory action of ACEI and ARB may also benefit the treatment of patients with metabolic syndrome, allergies, or autoimmune disorders.
Bryniarski et al. (Fri,) conducted a review in Hypertension. Angiotensin converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) was evaluated on Immunomodulatory properties. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers exhibit immune regulatory actions by inhibiting proinflammatory cytokine secretion and normalizing CRP concentrations.